Dr. Brad McGregor

We're opening other sites as well, looking to do

EV, SG, and PEMBRO in the frontline metastatic setting, you know, have a high bar.

EV, PEMBRO is great.

So we're looking for an 80% response rate.

But to your point, one of the things we're looking at is collecting blood to do CT analysis and look at CT and clearance as one of these novel endpoints to sort of better assess the activity.

So again, the idea of how do we make EV Pembroke better, that's one approach.

Add more, right?

And so we'll see how that plays out.

Yeah, I think one of the key questions is, are there HER2-positive, are they like not EV responders?

Like, what's the overlap there?

I think we don't know that data.

But I mean, I think that there's a lot of unanswered questions.

And I think as, you know, we start learning more about the mechanism of resistance of EV Pembroke,

I think there's going to be a lot more to be gained.

But I think HER2 is here to stay in bladder cancer.

Again, just like we have breast cancer, the HER2 ultra low, right?

And yet responses to TDXD.

I think with the cleavable payloads, right?

I mean, with the cleavable linkers, with those linkers that you don't have to have like 100% does get into lysosome.

I think that's key to some of these ADCs getting activity across a spectrum of positivities.